Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Thames Water Class B investors lose appeal against bailout plan

(Sharecast News) - Britain's Court of Appeal has ruled against campaigners and investors trying to stop the Thames Water's "eye-watering" £3bn emergency bailout, according to a decision published on Monday. A group of the utility's secondary "Class B" creditors appealed against a High Court decision last month to approve the plan proposed by Thames Water Utilities Holdings Limited weeks before it was due to run out of money on March 24.

The bondholders and campaigners said the loan servicing costs of 9.75% were not in the public interest and argued that the troubled company, labouring under debts of £19bn, should be put into temporary nationalisation under a special administration regime to save money.

Monday's ruling means the company can operate long enough to restructure debts and find new investment. The deal will give the company £1.5bn in cash from creditors, released monthly, plus up to £1.5bn more to see it through an appeal to try to increase bills by more than the 35% allowed by industry regulator Ofwat.

However, in a statement the Class B creditors said they were considering taking leave to appeal to the Supreme Court and will make a final decision once they have seen the wording of the judgement. No date has been set for publication.

Thames, which has 16 million customers and 8,000 employees, has been on the teetering on the verge of collapse for months amid severe criticism over its payout of billions in dividends to shareholders under previous owners and polluting rivers with sewage.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.